Shijiazhuang Yiling Pharmaceutical Future Growth
Future criteria checks 1/6
Shijiazhuang Yiling Pharmaceutical is forecast to grow earnings and revenue by 6.8% and 8.6% per annum respectively. EPS is expected to grow by 6.8% per annum. Return on equity is forecast to be 17.3% in 3 years.
Key information
6.8%
Earnings growth rate
6.8%
EPS growth rate
Pharmaceuticals earnings growth | 19.7% |
Revenue growth rate | 8.6% |
Future return on equity | 17.3% |
Analyst coverage | Good |
Last updated | 20 Mar 2024 |
Recent future growth updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2025 | 14,908 | 2,865 | N/A | 3,599 | 6 |
12/31/2024 | 12,972 | 2,462 | N/A | 3,093 | 6 |
12/31/2023 | 11,196 | 2,102 | N/A | 1,992 | 6 |
9/30/2023 | 13,162 | 2,706 | 2,162 | 2,408 | N/A |
6/30/2023 | 13,757 | 2,919 | 2,525 | 2,735 | N/A |
3/31/2023 | 13,746 | 3,080 | 3,087 | 3,343 | N/A |
12/31/2022 | 12,533 | 2,362 | 3,274 | 3,488 | N/A |
9/30/2022 | 9,951 | 1,535 | 1,094 | 1,473 | N/A |
6/30/2022 | 9,787 | 1,428 | 1,884 | 2,253 | N/A |
3/31/2022 | 9,170 | 1,153 | 575 | 1,141 | N/A |
1/1/2022 | 10,117 | 1,344 | -145 | 529 | N/A |
9/30/2021 | 10,447 | 1,426 | -576 | 300 | N/A |
6/30/2021 | 10,192 | 1,469 | -1,702 | -518 | N/A |
3/31/2021 | 10,117 | 1,455 | -1,005 | 179 | N/A |
12/31/2020 | 8,782 | 1,219 | 441 | 1,586 | N/A |
9/30/2020 | 7,925 | 1,048 | 442 | 1,314 | N/A |
6/30/2020 | 7,328 | 866 | 779 | 1,467 | N/A |
3/31/2020 | 6,609 | 756 | 529 | 1,043 | N/A |
12/31/2019 | 5,825 | 607 | -386 | 69 | N/A |
9/30/2019 | 5,336 | 612 | -193 | 208 | N/A |
6/30/2019 | 5,098 | 606 | 19 | 300 | N/A |
3/31/2019 | 4,784 | 577 | 370 | 593 | N/A |
1/1/2019 | 4,815 | 599 | -115 | 72 | N/A |
9/30/2018 | 4,848 | 653 | 320 | 462 | N/A |
6/30/2018 | 4,537 | 649 | 287 | 428 | N/A |
3/31/2018 | 4,347 | 632 | -105 | 66 | N/A |
12/31/2017 | 4,081 | 541 | -66 | 115 | N/A |
9/30/2017 | 3,972 | 555 | -3 | 242 | N/A |
6/30/2017 | 4,036 | 569 | N/A | 206 | N/A |
3/31/2017 | 4,050 | 570 | N/A | 508 | N/A |
12/31/2016 | 3,850 | 533 | N/A | 641 | N/A |
9/30/2016 | 3,665 | 527 | N/A | 507 | N/A |
6/30/2016 | 3,538 | 510 | N/A | 426 | N/A |
3/31/2016 | 3,439 | 489 | N/A | 181 | N/A |
12/31/2015 | 3,185 | 430 | N/A | 132 | N/A |
9/30/2015 | 3,161 | 395 | N/A | 60 | N/A |
6/30/2015 | 3,089 | 376 | N/A | -35 | N/A |
3/31/2015 | 2,980 | 377 | N/A | 56 | N/A |
12/31/2014 | 2,921 | 354 | N/A | 106 | N/A |
9/30/2014 | 2,877 | 312 | N/A | -80 | N/A |
6/30/2014 | 2,871 | 294 | N/A | 98 | N/A |
3/31/2014 | 2,711 | 275 | N/A | -35 | N/A |
12/31/2013 | 2,490 | 244 | N/A | 55 | N/A |
9/30/2013 | 2,416 | 248 | N/A | 127 | N/A |
6/30/2013 | 2,102 | 196 | N/A | 232 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 002603's forecast earnings growth (6.8% per year) is above the savings rate (2.9%).
Earnings vs Market: 002603's earnings (6.8% per year) are forecast to grow slower than the CN market (23.9% per year).
High Growth Earnings: 002603's earnings are forecast to grow, but not significantly.
Revenue vs Market: 002603's revenue (8.6% per year) is forecast to grow slower than the CN market (14.3% per year).
High Growth Revenue: 002603's revenue (8.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 002603's Return on Equity is forecast to be low in 3 years time (17.3%).